Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells

Abstract

TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ashkenazi A, Dixit VM . 1998 Science 281: 1305–1308

  • Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . 1999 J. Clin. Invest. 104: 155–162

  • Baeuerle PA, Baltimore D . 1996 Cell 87: 13–20

  • Beauparlant P, Kwan I, Bitaar R, Chou P, Koromilas AE, Sonenberg N, Hiscott J . 1994 Oncogene 9: 3189–3197

  • Beg AA, Baltimore D . 1996 Science 274: 782–784

  • Blay J-Y, Rossi J-F, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M . 1997 Int. J. Cancer 72: 424–430

  • Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L . 1997 Immunity 7: 821–830

  • Frank S, Kohler U, Schackert G, Schackert HK . 1999 Biochem. Biophys. Res. Commun. 257: 454–459

  • Gilmore TD, Koedood M, Piffat KA, White D . 1996 Oncogene 13: 1367–1378

  • Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . 1998 Blood 91: 4624–4631

  • Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S . 1999 Cancer Res. 59: 734–741

  • Kim K, Fisher MJ, Xu S-Q, El-Deiry WS . 2000 Clin. Cancer Res. 6: 335–346

  • Kothny-Wilkes G, Kulms D, Pöppelmann B, Luger TA, Kubin M, Schwarz T . 1998 J. Biol. Chem. 273: 29247–29253

  • Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldegrun A . 1997 Cancer Res. 57: 5189–5195

  • Pan G, Ni J, Wei Y-J, Yu G-L, Gentz R, Dixit VM . 1997 Science 277: 815–818

  • Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . 1996 J. Biol. Chem. 271: 12687–12690

  • Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . 1998 FEBS Letts. 427: 124–128

  • Ritchie AWS, Chisholm GD . 1983 Semin. Oncol. 10: 390–400

  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramarkrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A . 1997 Science 277: 818–821

  • Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenschein GE . 1997 J. Clin. Invest. 100: 2952–2960

  • Sumitomo M, Tachibana T, Ozu C, Asakura A, Murai M, Hayakawa M, Nakamura H, Takayanagi A, Shimizu N . 1999 Hum. Gene Ther. 9: 37–47

  • Tachibana M, Miyakawa A, Nakashima J, Murai M, Nakamura K, Kubo A, Hata J . 2000 Cell Tissue Res. 301: 353–367

  • Thornberry NA, Lazebnik Y . 1998 Science 281: 1312–1316

  • Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S . 1995 Genes Dev. 9: 2723–2735

  • Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Shuh JC, Lynch DH . 1999 Nat. Med. 5: 157–163

  • Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . 1998 Science 281: 1680–1683

  • Wang W, Abbruzzese JL, Evans DB, Larry L, Clleary KR, Chao PJ . 1999 Clin. Cancer Res. 5: 119–127

  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA . 1995 Immunity 3: 673–682

  • Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P . 1999 Cancer Res. 59: 2747–2753

Download references

Acknowledgements

This study was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mototsugu Oya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oya, M., Ohtsubo, M., Takayanagi, A. et al. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20, 3888–3896 (2001). https://doi.org/10.1038/sj.onc.1204525

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204525

Keywords

This article is cited by

Search

Quick links